Context Therapeutics Inc.
Context Therapeutics Inc. (CNTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CNTX · as of Sep 30, 2025
Ownership Breakdown
37
Institutional Holders
▼ 2 vs Q2
$66.82M
Total Inst. Value
▲ $21.86M vs Q2
91.88M
Shares Outstanding
freeFloat 70.37%
68.97M
13F Shares Held
▲ 346,686 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CNTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BIOIMPACT CAPITAL LLC pharmaceutical preparations | 14.71M | 15.45% | 15.45% | $14.25B | Nov 14, 2025 | — held |
AVIDITY PARTNERS MANAGEMENT LP pharmaceutical preparations | 8.98M | 9.44% | 9.44% | $8.70B | Nov 14, 2025 | ▲ 1.50M |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 7.42M | 7.79% | 7.79% | $7.19B | Nov 14, 2025 | — held |
NEXTECH INVEST, LTD. pharmaceutical preparations | 7.42M | 7.79% | 7.79% | $7.19B | Nov 14, 2025 | — held |
BLUE OWL CAPITAL HOLDINGS LP pharmaceutical preparations | 7.41M | 7.78% | 7.78% | $7.18B | Nov 12, 2025 | — held |
GREAT POINT PARTNERS LLC pharmaceutical preparations | 4.68M | 4.92% | 4.92% | $4.54B | Nov 14, 2025 | — held |
FRANKLIN RESOURCES INC pharmaceutical preparations | 4.00M | 4.21% | 4.21% | $3.88B | Nov 13, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 3.50M | 3.67% | 3.67% | $3.39B | Nov 7, 2025 | ▲ 134.4K |
BLACKSTONE INC. pharmaceutical preparations | 2.44M | 2.56% | 2.56% | $2.36B | Nov 14, 2025 | — held |
ALYESKA INVESTMENT GROUP, L.P. pharmaceutical preparations | 1.66M | 1.75% | 1.75% | $1.61B | Nov 17, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
7
Increased
+1.71M shares5
New Positions
first time holders7
Decreased
−533.9K shares7
Sold Out
fully exitedNet shares change (top 50)
+1.17M
+1.71M / −533.9K
Net new holders
-2
5 new / 7 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CNTX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
10
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Levit Alex C. Chief Legal Officer, Corp. Sec | Feb 19, 2026 | Award | 270,000 | $2.32 | $626.4K | 270.0K | Form 4 ↗ |
Minai-Azary Jennifer Lynn Chief Financial Officer | Feb 19, 2026 | Award | 275,000 | $2.32 | $638.0K | 275.0K | Form 4 ↗ |
Chagin Karen Deborah Chief Medical Officer | Feb 19, 2026 | Award | 290,000 | $2.32 | $672.8K | 290.0K | Form 4 ↗ |
Lehr Martin A. Chief Executive Officer | Feb 19, 2026 | Award | 815,000 | $2.32 | $1.89M | 815.0K | Form 4 ↗ |
Pasternak Andy director | Jun 12, 2025 | Award | 138,900 | $0.65 | $90.7K | 138.9K | Form 4 ↗ |
Kantoff Philip W. director | Jun 12, 2025 | Award | 123,500 | $0.65 | $80.6K | 123.5K | Form 4 ↗ |
Smith Karen L. director | Jun 12, 2025 | Award | 123,500 | $0.65 | $80.6K | 123.5K | Form 4 ↗ |
Stacey Jennifer Evans director | Jun 12, 2025 | Award | 123,500 | $0.65 | $80.6K | 123.5K | Form 4 ↗ |
Walker Luke Nathaniel director | Jun 12, 2025 | Award | 123,500 | $0.65 | $80.6K | 123.5K | Form 4 ↗ |
West Linda director | Jun 12, 2025 | Award | 123,500 | $0.65 | $80.6K | 123.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Context Therapeutics Inc. (CNTX) is primarily owned by institutional investors, who hold approximately 75.1% of total shares outstanding. Company insiders own approximately 29.63%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Context Therapeutics Inc. is BIOIMPACT CAPITAL LLC, holding approximately 14.71 million shares — equal to 15.45% of outstanding shares — as of September 30, 2025.
A total of 37 institutional investors currently hold CNTX stock, with a combined institutional value of approximately $66,815,968 as of the most recent 13F filing period.
Frequently asked questions
CNTX ownershipContext Therapeutics Inc. (CNTX) is primarily owned by institutional investors, who hold approximately 75.1% of shares. The largest shareholder is BIOIMPACT CAPITAL LLC with a 15.45% stake. Company insiders hold 29.63%. Data sourced from SEC Form 13F as of September 30, 2025.